Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HHS Secretary Leavitt Calls For “Explicit Extraterritorial Jurisdiction” For U.S. FDA

This article was originally published in PharmAsia News

Executive Summary

U.S. Health and Human Services Secretary Michael Leavitt requested Congress in a Feb. 22 letter to grant FDA "explicit extraterritorial jurisdiction" to investigate manufacturers whose products are subject to the Federal Food, Drug, and Cosmetic Act

You may also be interested in...



Contaminant Discovered In Chinese-Produced Heparin API

U.S FDA has discovered "significant quantities" of a heparin-like contaminant in tested samples of heparin API manufactured by Baxter-supplier Scientific Protein Laboratories' Changzhou plant

Contaminant Discovered In Chinese-Produced Heparin API

U.S FDA has discovered "significant quantities" of a heparin-like contaminant in tested samples of heparin API manufactured by Baxter-supplier Scientific Protein Laboratories' Changzhou plant

Baxter’s Chinese API Supplier Cited For “Objectionable Practices;” Remaining Heparin Vials Recalled

U.S. FDA has issued a Form 483 to Changzhou SPL, Baxter Healthcare's heparin API supplier, after inspecting the Changzhou City plant, FDA announced Feb. 28 during an update of the agency's ongoing investigation of Baxter's heparin products

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

SC067738

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel